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ABSTRACT
S100A4 (metastasin-1), a metastasis-associated protein and marker of the
epithelial to mesenchymal transition, contributes to several hallmarks of cancer and
has been implicated in the progression of several types of cancer. However, the impacts
of S100A4 signaling in lung cancer progression and its potential use as a target for
therapy in lung cancer have not been properly explored. Using established lung cancer
cell lines, we demonstrate that S100A4 knockdown reduces cell proliferation, invasion
and three-dimensional invasive growth, while overexpression of S100A4 increases
invasive potential. In patient-derived tissues, S100A4 is preferentially elevated in
lung adenocarcinoma. This elevation is associated with lymphovascular invasion and
decreased overall survival. In addition, depletion of S100A4 by shRNA inhibits NFκB activity and decreases TNFα-induced MMP9 expression. Furthermore, inhibition
of the NF-κB/MMP9 axis decreases lung carcinoma invasive potential. Niclosamide,
a reported inhibitor of S100A4, blocks expression and function of S100A4 with a
reduction in proliferation, invasion and NF-κB-mediated MMP9 expression. Collectively,
this study highlights the importance of the S100A4/NF-κB/MMP9 axis in lung cancer
invasion and provides a rationale for targeting S100A4 to combat lung cancer.

of targeted agents show promise for the treatment of
NSCLC, however, patients with advanced disease often
develop resistance to these therapies [2, 3]. Therefore,
there is an urgent need to better understand the crucial
drivers of the metastatic process and to explore and
develop novel therapeutic agents to reduce the morbidity
and mortality associated with NSCLC.
S100A4 (also known as metastasin-1 (mts1)/fibroblast
specific protein (FSP1)) is a calcium binding EF-hand
protein that has been implicated in carcinoma progression
and is a marker of the epithelial to mesenchymal transition

INTRODUCTION
A majority of lung cancer patients present at an
advanced stage, which often precludes treatment with
surgical resection alone [1]. Non-small cell lung cancer
(NSCLC) accounts for roughly 85% of all lung cancers,
and includes multiple histologic subtypes such as
adenocarcinoma (ADC) and squamous cell carcinoma
(SCC). Despite recent advances in screening and therapy,
the prognosis for NSCLC remains poor, with only 15% of
patients surviving five years after diagnosis [1]. A number
www.impactjournals.com/oncotarget
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(EMT) [4–6]. S100A4 has been identified in the nucleus,
cytoplasm and extracellular space, suggesting that it signals
through both intracellular and extracellular mechanisms
[7]. Intracellular S100A4 interacts with a number of target
proteins, such as p53, [8] and the heavy chain of non-muscle
myosin IIA (MHC-IIA) [9]. We have shown that S100A4
interacts with Rhotekin to facilitate the formation of cell
membrane protrusions and promote invasive growth in
carcinoma cells [7]. S100A4 is secreted by both cancer and
stromal cells to participate in both paracrine and autocrine
signaling through its putative receptor RAGE, as well as
through EGFR- and Toll-like receptor-4 (TLR-4)-mediated
pathways. S100A4 can also activate NF-κB, thus stimulating
a pathway that promotes proliferation and cell survival in
multiple tumor types [10]. Collectively, through these
intracellular and extracellular actions, S100A4 contributes
to several hallmarks of cancer, including cell survival and
proliferation, angiogenesis, invasion and metastasis, and
tumor-promoting inflammation [11, 12]. Through these
extensive biological functions, S100A4 expression is
associated with tumor progression and is identified as a
prognostic indicator in many human malignancies [6].
Despite extensive investigation of S100A4 in
carcinoma progression, the impact of S100A4 signaling
in lung cancer is poorly defined. In this study, we
investigated the contribution of S100A4 in lung cancer
cell invasion, determined the clinical significance of
S100A4 expression in patient-derived lung cancer tissues,
and provided a rational for targeting S100A4 signaling
through repurposing an FDA-approved drug.

of S100A4 in H1299 cells promoted cell invasion and
invasive growth in the 3D system (Figure 1H-1J) but did
not increase cell proliferation (data not shown), suggesting
that the effect of S100A4 in promoting proliferation is cell
context-dependent. Collectively, these data demonstrate
that S100A4 drives an invasive phenotype in lung cancer
cells.

S100A4 is overexpressed in patient-derived
lung adenocarcinomas and associates with poor
prognosis
We constructed a lung cancer tissue microarray
(TMA) and stained sections for S100A4 using
immunohistochemistry in order to examine S100A4
expression in patient-derived tissues (N = 212). A
wide range of staining intensities was observed in
lung carcinoma cells, which were scored using a semiquantitative scale ranging from 0 to 3 (Figure 2). In
addition, positive staining was observed in lymphocytes
and macrophages, which served as positive internal
controls (data not shown). Next, we correlated S100A4
expression with clinical and pathological features. We
found that S100A4 was preferentially overexpressed in
lung adenocarcinoma when compared to squamous cell
carcinoma (Figure 3A), which was confirmed using a
publicly available gene expression dataset (Figure 3B).
S100A4 overexpression was much less common among
the other histologic subtypes as only 9.7% of these
samples exhibited elevated levels of S100A4 expression
(Supplementary Table 2). Furthermore, we found that
S100A4 overexpression was associated with the presence
of lymphovascular invasion (Table 1) and decreased
overall survival among patients with lung adenocarcinoma
(Figure 3C; median survival: 29.5 versus 70 months,
hazard ratio 2.62, 95% confidence interval 1.133 to 6.035,
P = 0.0243). When all histologic subtypes were combined,
there was no significant difference in median survival
between patients with and without S100A4 overexpression
(Figure 3D; hazard ratio 1.220, 95% confidence interval
0.6904 to 2.157, P = 0.4692). This observation suggests
that S100A4 overexpression has a higher impact in the
lung adenocarcinoma subpopulation when compared to
the squamous cell carcinoma subpopulation.

RESULTS
S100A4 drives the invasive potential of lung
cancer cells
We used a panel of established lung cancer cell lines
with different genetic backgrounds (Supplementary Table
1) to examine S100A4 expression in lung cancer cells by
immunoblot (Figure 1A) and Q-PCR (Figure 1B). S100A4
was highly expressed in about 50% of cell lines tested
(Supplementary Table 1). Culturing cells in 3D Matrigel
is commonly used to assess physiologically relevant
tumorigenesis, morphogenesis and invasive potential [13,
14]. To test the contribution of S100A4 to lung cancer cell
proliferation and invasive potential, loss-of function and
gain-of function studies were performed in combination
with 3D Matrigel analyses. S100A4 was depleted in
A549 and H460 cells using lentiviral-based shRNA.
Cells were grown in 3D Matrigel with growth media
containing 2% FBS. Efficient knockdown of S100A4 in
A549 cells (Figure 1C and 1D) dramatically decreased cell
proliferation (Figure 1E) and invasive growth in the 3D
Matrigel (Figure 1F and 1G). Similar results were observed
in H460 cells (Supplementary Figure 1) and H358 cells
(Supplementary Figure 2). In contrast, overexpression
www.impactjournals.com/oncotarget

Niclosamide, an FDA-approved drug, targets
S100A4 to abbrogate the invasive potential of
lung cancer cells
Niclosamide affects multiple signaling pathways
that are important in cancer progression and has also
been shown to block S100A4 expression in colon cancer
cells [15, 16]. Our data show that S100A4 drives an
invasive phenotype in lung cancer cells (Figure 1), thus
positioning S100A4 as a potential target for the treatment
of advanced NSCLC. Therefore, we investigated whether
34631
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niclosamide also suppresses S100A4 expression in lung
cancer cells and whether it inhibits S100A4-mediated
functions. Niclosamide blocked S100A4 expression in
lung carcinomas both at the mRNA (Figure 4A) and
protein levels (Figure 4B) in a dose-dependent manner.
This inhibitory effect of niclosamide on lung cancer cell
proliferation was also investigated using H358 and A549
cells treated with varied concentrations of niclosamide.
We performed direct cell count or MTT assay to assess the
number of viable cells over 3-5 days. Niclosamide treatment
dramatically decreased the proliferation of H358 cells

(Figure 4C) and A549 cells (Figure 4D), at concentrations as
low as 0.5 μM. We then evaluated the effect of niclosamide
treatment on the invasive capacity of A549 cells using
Transwell invasion assays and by monitoring invasive
growth in the 3D Matrigel system. As visualized in Figure
4E, niclosamide treatment decreased EGF-stimulated
A549 cell invasion. Consistent with these observed effects
on proliferation and invasion, niclosamide significantly
inhibited invasive growth in the 3D Matrigel (Figure 4F
and 4G). These data demonstrate that niclosamide blocks
the invasive capabilities of lung cancer cells driven by

Figure 1: S100A4 drives the invasive potential of lung cancer cells. A and B. Lung cancer cells as indicated were lysed in RIPA
buffer, total cell lysates (80μg) were subjected to 15% SDS-PAGE, transferred and immunoblotted with rabbit anti-S100A4 antibody (A).
RNA was isolated from cells and quantitative real time PCR (Q-PCR) was used to assess S100A4 expression levels (B). C-G. A549 cells
with stable knockdown of S100A4 by shRNA targeting S100A4 (shS100A4) or expressing a non-targeting control (shCont) were generated.
S100A4 expression was assessed by immunoblot analysis (C) and Q-PCR (D). Cell proliferation in standard (2D) culture was assessed by
MTT (E). Cells were grown in 3D Matrigel for 5 days and representative phase contrast images for control and knockdown cells are shown
(F). The diameter of 70-120 colonies from randomly chosen fields was measured, quantified for average colony volume and presented in
(G). H-J. H1299 cells, stably transfected with pIRES-GFP-S100A4 (GFP-S100A4) or pIRES-GFP alone (GFP), were assessed for S100A4
expression by immunoblot analysis (H) or for invasion toward 1% FBS overnight (I) or grown in 3D Matrigel for 5 days (J). Representative
data from at least three independent experiments are shown. Error bars represent the SEM of the mean in (G) and the SD of the mean from
at least three replicates in (B, D, E and I). Arrows indicate invasive growth. Scale bar in (F and J) = 50μm. * indicates p<0.05.

www.impactjournals.com/oncotarget
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Figure 2: S100A4 expression patterns in non-small cell lung carcinoma. A-D. Examples of negative (A), weak (B), moderate
(C), and strong (D) S100A4 expression in non-small cell lung cancers (left panels), with corresponding hematoxylin and eosin stained
(H&E) sections (right panels). Magnification = 200X for all images.

Figure 3: S100A4 is overexpressed in lung adenocarcinoma, where it associates with decreased overall survival. A-D.
Using semi-quantitative IHC data from our TMA, we found that S100A4 levels were significantly elevated in adenocarcinoma (ADC) when
compared to squamous cell carcinoma (SCC, A), which was confirmed using an external gene expression dataset (B). In patients with lung
adenocarcinoma, elevated expression of S100A4 (>2.5) correlated with shorter median survival (C). A significant relationship between
elevated S100A4 expression and overall survival was not identified when examining all histologic subtypes (NSCLC) combined (D).
www.impactjournals.com/oncotarget
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Table 1: Clinico-pathologic parameters and S100A4 expression in lung adenocarcinoma patients
S100A4 High (>2.5)

S100A4 Low (≤2.5)

17/81 (21%)

64/81 (79%)

≥ 65 years

10/38 (26%)

28/38 (74%)

< 65 years

7/43 (16%)

36/43 (84%)

Stage I-II

10/53 (19%)

43/53 (81%)

Stage III-IV

6/24 (25%)

18/24 (75%)

N0

10/50 (20%)

40/50 (80%)

N1 or N2

6/26 (23%)

20/26 (77%)

Present

10/25 (40%)

15/25 (60%)

Absent

7/56 (12.5%)

49/56 (87.5%)

Present

6/33 (18%)

27/33 (82%)

Absent

11/48 (23%)

37/48 (77%)

Adenocarcinoma

P value

Age at diagnosis
P = 0.2893

Collaborative Stage
P = 0.5556

Lymph node metastasis
P = 0.7731

Lymphovascular invasion
P = 0.0080

Pleural Invasion

S100A4. To analyze the specific contribution of S100A4
to anti-tumor activity of niclosamide, we performed an
invasion assay as we did in Figure 1I on H1299 cells stably
expressing a bicistronic S100A4-pIRES-EGFP vector
in the presence and absence of nicosamide. In this assay
S100A4 expression level is not subject to regulation by
niclosamide. We found that overexpressing S100A4 did
not prevent the inhibitory effect of niclosamide, instead,
niclosamide significantly inhibited S100A4-mediated
invasion to the basal level (Supplementary Figure 4). These
results suggest that niclosamide inhibited lung cancer
cell invasive potential is not only limited to suppression
of S100A4 expression but also extended to inhibition of
S100A4 signaling-mediated function.

translocated into the nucleus where it activates a variety of
genes that promote cell proliferation, survival and invasion
[18, 19]. To test whether depletion of S100A4 inhibits
the NF-κB pathway, we evaluated NF-κB activity using
a luciferase activity assay and p65 nuclear translocation.
Control (shCont) and S100A4 knockdown (shS100A4)
A549 cells were transfected with an NF-κB luciferase
reporter gene construct and treated with 5 ng/ml TNF-α.
As shown in Figure 5A, knockdown of S100A4 not only
decreased TNF-α induced NF-κB activity, but also reduced
the basal activity of NF-κB. We then investigated whether
depletion of S100A4 inhibits p65 nuclear translocation. As
shown in Figure 5C, knockdown of S100A4 in A549 cells
decreased p65 nuclear localization in response to TNF-α
treatment. To determine the biological consequences
of NF-κB inhibition, a Matrigel invasion assay was
performed with TNF-α as the attractant in A549 shCont
and shS100A4 cells. We observed that cells with S100A4
knockdown (shS100A4) displayed decreased invasive
potential (Supplementary Figure 3). Since niclosamide
treatment suppressed S100A4 expression and decreased
the invasive potential of lung cancer cells (Figure 4), we
hypothesized that treatment with niclosamide would block
NF-κB activity. To test this hypothesis, we performed
an NF-κB luciferase activity assay and p65 nuclear
translocation in response to TNF-α with and without
niclosamide treatment. Niclosamide treatment decreased
NF-κB luciferase activity and inhibited p65 nuclear

Inhibition of S100A4 decreases NF-κB activity
Considerable evidence demonstrates that NFκB signaling is constitutively activated in solid tumors
and is essential for lung cancer tumorigenesis, invasion
and metastasis [17]. S100A4 has been shown to affect
canonical NF-κB signaling through cross-talk with RAGE,
TLR-4 and EGFR. In the canonical NF-κB pathway, p65
(RelA) and p50 form a heterodimer that is sequestered by
IkB-α under unstimulated conditions. Stimulation with
cytokines, such as TNF-α, activates the IkB kinase (IKK)
complex, which phosphorylates IkB-α, leading to its
degradation. NF-κB is then released, phosphorylated and
www.impactjournals.com/oncotarget
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S100A4 is required for TNF-α-induced and
NF- κB-mediated MMP9 expression

translocation in A549 cells (Figure 5B and 5D). Similar
results were seen using H460 cells (data not shown).
Taken together, these data show that S100A4 drives lung
cancer invasion by activating NF-κB activity. These data
also suggest that the inhibitory effect of niclosamide on
NF-κB activity could be, at least in part, due to S100A4
suppression.

TNF-α induces MMP9 expression through the NFκB pathway [20]. We tested whether inhibition of S100A4
affects downstream targets of NF-κB such as MMP9.
We used Q-PCR to assess the expression of MMP9 in

Figure 4: Niclosamide decreases S100A4 expression, lung cancer cell proliferation, invasion and invasive growth.

A and B. A549 cells were treated with niclosamide at the indicated concentrations for 72 hrs, and S100A4 expression was assessed
by Q-PCR (A) or immunoblotting analysis (B). C and D. Cells were treated with varied concentrations of niclosamide for 1-5 days
and then cell number assessed by either direct cell count (C, H358) or MTT assay at various time intervals (D, A549). E. A549 cells
were treated with niclosamide at the indicated concentrations for 3 days, trypsinized and assessed for EGF-stimulated (5 ng/ml) Matrigel
invasion in the presence or absence of niclosamide. F, G. A549 cells were cultured in 3D Matrigel with or without 1 μM niclosamide for
6 days. Representative phase contrast images are shown (F). The diameter of 70-120 colonies from randomly chosen fields was measured,
quantified for average individual colony volume (G). Representative data from at least three independent experiments are shown. Error bars
represent the SEM of the mean in (G) and the SD of the mean from at least three replicates in (A, C, D and E). Scale bar in (F) = 100 μm.
* indicates p<0.005. ** indicates p<0.0001.
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A549 shCont and shS100A4 cells with and without
TNF-α. Knockdown of S100A4 significally decreased
basal expression of MMP9 in H358 (Supplementary
Figure 2C) and A549 cells as well as TNF-α-induced
MMP9 expression (Figure 6A). In addition, niclosamide
treatment, which decreases S100A4 expression (Figure
4) and NF-κB activity (Figure 5), results in a significant
inhibiton of TNF-α-induced MMP9 expression in A549
cells (Figure 6B). Collectively, these data support the
assertion that S100A4 confers an invasive phenotype, at
least in part, through the NF-κB pathway. To substantiate
the finding that MMP9 expression depends on NF-κB, we
blocked the NF-κB pathway by using the NF-κB inhibitor,
wedelolactone, which directly inhibits the phosphorylation
and degradation of IκBα, and by reducing RelA (p65)
expression using a lentiviral-based shRNA. As shown in
Figure 6C, pretreatment of A549 cells with wedelolactone
prior to stimulation with TNF-α dramatically decreased
MMP9 expression. Efficient RelA knockdown

significantly abrogated TNF-α-induced MMP9 expression
(Figure 6D and 6E).

The NF-ĸB/MMP9 pathway is critical to the
invasive potential of NSCLC cells
Our data demonstrate that S100A4 drives the
invasive capacity of lung cancer cells, affects the NF-κB
pathway, and acts as an essential component of TNF-αinduced and NF-κB-dependent MMP9 expression. Next,
we investigated whether the NF-κB/MMP9 axis is critical
to the invasive capacity of lung cancer cells. Accordingly,
we pretreated A549 cells with inhibitors of either NFκB or MMP2/MMP9, then performed Matrigel invasion
assays. Inhibition of the NF-κB/MMP9 pathway not only
decreased the basal invasive capacity but also inhibited
cell invasion toward chemo-attractants such as TNF-α
and EGF (Figure 6F). Collectively, these results implicate
S100A4 in driving lung cancer invasive potential, at least
in part, through activation of the NF-κB/MMP9 axis.

Figure 5: Inhibition of S100A4 decreases NF-κB activity. A and B. A549 shCont and shS100A4 cells (A) or A549 parental cells

(B) were transfected with NF-κB firefly luciferase reporter and TK-renilla luciferase control, treated with 5 ng/ml TNF-α with or without
niclosamide at indicated concentrations for 24 hrs before harvesting for Dual luciferase activity assays. C. A549 shCont and shS100A4
cells (C) were serum starved overnight, then stimulated with 5 ng/ml TNF-α for 4 hrs before harvesting for cell fractionation. D. A549
parental cells were treated with 0.5 μM niclosamide for 48 hrs, serum starved in the presence or absence of niclosamide overnight, then
stimulated with 5 ng/ml TNF-α for 4 hrs before harvesting for cell fractionation. Nucleic and cytosolic proteins were separated by SDSPAGE, transferred and probed for p65, p84 and GAPDH. Representative data from at least three independent experiments are shown. Error
bars represent the SD of the mean from three replicates. (*) and (#) in (A) indicate p<0.05 compared to control and TNF-α treated shCont
cells, respectively. (*) and (#) in (B) indicate p<0.001 compared to control and TNF-α treated cells, respectively.

www.impactjournals.com/oncotarget
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DISCUSSION

that in lung adenocarcinoma patients, S100A4 elevation
was associated with reduced overall survival as well as
lymphovascular invasion, a marker of poor prognosis in
many cancers. A similar association between elevated
S100A4 expression and lymphovascular invasion has
previously been demonstrated in colorectal carcinoma
[25]. Taken together, these data suggest that S100A4 could
serve as a marker of poor prognosis as well as a valuble
therapeutic target in lung cancer.
It is well established that S100A4 overexpression
contributes to several hallmarks of cancer. Supported
by a previous study [26], we found that depletion of
S100A4 inhibited cell proliferation in both H358 and
A549 cells. However, forced expression of S100A4
alone in H1299 cells is not sufficient to promote cell
proliferation, suggesting that the role of S100A4 in cell
proliferation could be cell context dependent. Recent
studies demonstrate that S100A4 promotes lung cancer
cell mortility and cell growth [27], although the detailed
mechanisms have not been fully defined. Notably,

The majority of patients with advanced NSCLC
die within 18 months of diagnosis, usually as a result of
metastatic disease [21, 22]. Elucidation of the mechanisms
driving lung cancer invasion and metastasis can lead to
the development of therapies targeting these pathways
which, in turn, will have significant impacts on patient
survival and quality of life. S100A4 is known to promote
aggressive behavior in human cancers [6] and can be
induced by cigarette smoke [Monzon ME, et.al., Am J
Resp Crit Care. 2011; 183. Meeting Abstract]. S100A4 is
often overexpressed in NSCLC as well as other tobaccorelated malignancies, making it an excellent therapeutic
target for lung and other cancers. As published in other
reports [23, 24], we found that S100A4 expression was
elevated in lung adenocarcinoma. However, due to
the small sample size and lack of non-smokers in our
population, we could not confirm an association between
S100A4 expression and tobacco exposure. We found

Figure 6: The S100A4/NF-κB/MMP9 axis is critical to the invasive capacity of lung cancer cells. A-C. Cells were exposed
to a variety of experimental conditions and then TNF- α was added for an additional 24 hrs prior to assessment of MMP9 expression by
Q-PCR. A549 shCont and shS100A4 cells treated with 5 ng/ml TNF-α for 24 hrs (A), or parental A549 cells were pretreated with 1μM
niclosamide for 48 hrs (B), or parental A549 cells treated with 10 μM and 50 μM Wedelolactone (WEL) for 24 hrs (C). D-E. A549 shCont
and shRelA cells were treated with 5 ng/ml TNF-α for 24 hrs, then harvested and assessed for MMP9 (D) and RelA (E) expression by
Q-PCR. F. Parental A549 cells were pretreated with 10 μM Wedelolactone or 100 μM MMP2/9 inhibitor I for 24 hrs, trypsinized, rinsed
and assessed for Matrigel invasion toward 5 ng/ml TNF-α or 5 ng/ml EGF overnight in the presence or absence of the respective inhibitors.
Representative data from at least three independent experiments are shown. Error bars represent the SD of the mean from three replicates.*
indicates p<0.05, ** indicates p<0.01.
www.impactjournals.com/oncotarget
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39]. Niclosamide inhibits S100A4 through the Wnt/βcatenin pathway in colon cancer [16]. Our study extends
current understanding by showing that at physiologically
achievable levels, niclosamide can effectively target the
S100A4/NF-κB/MMP9 signaling axis in lung cancer by
decreasing S100A4 expression. This decrease in S100A4
expression in turn decreases NF-κB activity and NFκB-mediated MMP9 expression. Given that S100A4
is secreted and can be detected in patient serum, our
study suggests that S100A4 could be used as a potential
biomarker to monitor the response to niclosamide
treatment, although in vivo studies are needed to confirm
this concept.
Our study highlights the important role of the
S100A4/NF-κB/MMP9 signaling axis in promoting lung
cancer invasive capacity, and demonstrates that S100A4
overexpression associates with reduced overall survival
among patients with lung adenocarcinoma. Importantly,
our study demonstrates that niclosamide dramatically
inhibits the NF-κB/MMP9 signaling axis by suppressing
S100A4 to block the invasive capacity of lung cancer cells.
Since S100A4 promotes metastasis, our study provides
strong evidence and rationale for targeting S100A4 by
repurposing niclosamide to block invasion and prevent
metastasis in NSCLC.

extracellular S100A4 has been shown to activate canonical
NF-κB pathway through activation of IκB-α [10, 28–31].
NF-κB signaling is constitutively activated in solid tumors
including lung cancer [32] and is essential for lung cancer
tumorigenesis, invasion and metastasis [17]. Although NFκB has been considered as a therapeutic target, its role in
normal physiology poses a substantial challenge for directly
targeting NF-κB for cancer therapy. Therefore, alternatively
targeting the upstream or downstream pathways that lead to
constitutive NF-κB activation may be more sucessful [33].
Our data demonstrated that inhibition of S100A4 decreased
NF-κB p65 nuclear translocation in response to TNF-α.
We also found that depletion of S100A4 decreased the
basal activity of NF-κB signaling. Inhibition of the NF-κB
pathway dramatically blocked the invasive capacity of lung
cancer cells, suggesting that inhibition of S100A4 signaling
could effectively mitigate NF-κB-mediated effects.
Matrix metalloproteinases (MMPs) are essential
in tumor invasion and metastasis due to their abilities
to degrade the extracellular matrix (ECM) and also
to change cellular behavior to modulate the tumor
microenvironment. Downstream of the NF-κB pathway,
we found that MMP9, but not MMP2, was dramatically
inhibited by S100A4 depletion in response to TNF-α (data
not shown). Importantly, MMP9 inhibition decreased the
TNF-α- and EGF-stimulated invasiveness of A549 cells,
highlighting the importance of the S100A4/MMP9 axis in
S100A4-driven invasion in lung cancer cells. Given that
S100A4 is an established metastasis-promoting protein,
it is not surprising that this S100A4/MMP9 pathway is
demonstrated in other cancer types [34]. In support of
our study, recent work has shown that both S100A4 and
MMP9 are upregulated in patient-derived lung cancer
tissues and positively correlate with each other [23],
further implicating the importance of S100A4/MMP9
signaling in lung cancer progression.
Currently, there is no clinically available treatment
targeting S100A4 and its pleiotropic roles in cancer
progression. Multiple strategies have been proposed to
block S100A4 function in cancer. These strategies include
targeting S100A4 with specific antibodies or interfering
with the interaction of S100A4 and its targets using
small molecular inhibitors [35, 36]. However, S100A4
is often present at high concentrations in malignancies,
and is also high in inflammatory disorders [37, 38], which
complicates the use of antibodies to inhibit S100A4
signaling extracellularly and/or through blocking the
intracellular action. Niclosamide, an anti-helminthic
agent used for over 50 years to treat tapeworm infections
in humans, is proposed to have a favorable safety profile
due to poor systemic absorption from the gastrointestinal
tract [15]. However, animal studies have shown that
the concentration of niclosamide in tumor tissue and
plasma can reach up to 1 μM, thus revealing that it is
readily absorbed without significant toxicity to normal
fibroblasts and peripheral blood mononuclear cells [15,
www.impactjournals.com/oncotarget

MATERIALS AND METHODS
Cell lines and reagents
Lung cancer cell lines that are representative of
different subtypes of lung cancer were obtained from
ATCC. Lung adenocarcinoma (A549, EKVX, H358,
Hop62, H322M, H522, H838, and H23), large cell lung
carcinoma (H460, Hop92), NCSLC (H1299, H810)
and small cell lung cancer (H82) cell lines were used in
this study. A549, H1299, H358 and H460 cells used for
biological functional analysis were authenticated with
short tandem repeat (STR) profile analysis by Genetica
DNA laboratories in May 2015. Niclosamide and
Wedelolactone were obtained from Sigma-Aldrich (St.
Louis, MO). MMP2/9 inhibitor I was from Calbiochem/
EDM Millipore (Billerica, MA). The pIRES-GFP-S100A4
construct was obtained from Dr. Masashi Fukayama
(University of Tokyo, Tokyo, Japan) [40].

Immunoblotting
Cells were harvested and lysed in RIPA buffer (150
mM NaCl, 0.5 mM EGTA, 0.5% sodium deoxycholate,
0.1% SDS, 1% Triton X-100, 50 mM Tris-HCl pH 7.4,
15 μg/ml protease inhibitor cocktail, 1 mM PMSF, 50
mM NaF and 10 mM sodium pyrophosphate). Total cell
lysates (80 μg) were subjected to 10% or 15% SDS-PAGE,
transferred and immunoblotted with rabbit anti-S100A4
antibody (Dako, Carpinteria, CA), p65 (Santa Cruz,
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Quantitative real time PCR (Q-PCR)

Dallas, TX) or p84 (GeneTex, Irvine, CA). Tubulin and
β-actin antibodies were from Sigma-Aldrich and were
used as the loading controls.

Total RNA was extracted using TRizol reagent (Life
Technologies/ThermoFisher, Grand Island, NY). Total
RNA (1μg) was used to reverse-transcribe into cDNA
using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems/ThermoFisher, Grand Island, NY).
Expression of target genes was assessed by Comparative
Ct (∆∆Ct) using commercially available probes and
master mix reagent and performed on a StepOnePlusTM
96-well instrument as described by the manufacturer
(Applied Biosystems). The expression level of each gene
was normalized by 18S or β-actin RNA and reported as a
relative level to a specified control, as noted.

Three-dimensional (3D) culture
Culturing lung cancer cells in 3D was performed as
described previously [14]. Briefly, cells (1 x 104) in 200 μl
growth media with 2% FBS were seeded onto solidified
growth factor-reduced Matrigel (BD Biosciences, San
Jose, CA; 100 μl per well of 8-well chamber slide) and
then covered with medium containing 10% Matrigel.
The next day, DMSO or niclosamide at the indicated
concentration was added to the cultures. When the control
cells developed an invasive growth phenotype (approx.
5-6 days), phase contrast images of randomly chosen
fields were taken with a Nikon Ti-E inverted microscope
and analyzed using Nikon Elements software.

Stable lentiviral shRNA cell line generation
For stable reduction of S100A4 expression in A549
and H460 cells, lentivirus-mediated shRNA construct
pLKO.1-puro targeting human S100A4 (S100A4-#A6)
or containing non-targeting sequence (Sigma-Aldrich)
were packaged into virus. In brief, the control or
S100A4-specific shRNA construct was co-transfected with
Mission lentiviral packaging mix (Sigma-Aldrich) into
293T cells using polyethylenimine (PEI) based on 1:3 ratio
of DNA: PEI. The viral supernatant was collected 48 hrs
after transfection, as described previously [7]. Then, A549
and H460 cells were infected with virus containing media
and stable transfectants were selected with puromycin
(2 μg/ml). The targeting sequences for human S100A4
are 5’ aagctcaaca agtcagaact aaa (#A6) and
5’CGCCATGATGTGTAACGAATT 3’ (#A8).

Matrigel invasion assay
Matrigel (10 μg, BD Biosciences) was dried onto the
upper well of transwell chambers (6.5-mm diameter, 8-μm
pore size, Corning, Corning, NY). One hour before the
assay, Matrigel was reconstituted with 100 μl of serumfree medium and the bottom chamber was coated with 5
μg/ml fibronectin. Cells (70% confluent) were trypsinized
and rinsed three times with serum-free medium plus
250 μg/ml BSA. Cells (5x104) were added to the upper
chamber, and medium/BSA containing 5 ng/ml EGF,
5 ng/ml TNF-α or 1% FBS (control) was added to the
bottom chamber as indicated; cells were allowed to invade
overnight at 37°C. Non-invaded cells were removed from
the top chamber using a cotton swab; invaded cells on the
bottom of the transwell membrane were fixed with 100%
methanol and stained with 1% crystal violet. Four fields
per well were counted and averaged, and the data were
presented as the mean number of cells invaded per mm2
+/- standard deviation from triplicate determinations.

Generation of S100A4 overexpression cell lines
H1299 cells in 10-cm dishes were transfected with 8
μg GFP control or pIRES-GFP-S100A4 constructs using
Lipofectamine 2000 (Invitrogen/ThermoFisher, Grand
Island, NY). Transfected cells were selected with G418
(400 μg/ml) and sorted for GFP by fluorescence activated
cell sorting (FACS).

Cell proliferation assays

Tissue microarray (TMA) construction and
immunohistochemistry (IHC) staining

Cell proliferation was assessed by direct cell
counting or by 3-(4, 5-dimethylthiazol-2-yl)-2.5diphenyltetrazolium bromide (MTT) assay. Cells (0.5
x105) were seeded in each well of a 12-well plate for
direct cell counting or cells (2x103) were seeded in each
well of a 96-well plate for MTT assay. For niclosamide
treatment, fresh growth media containing niclosamide
or DMSO was added starting the day after plating, and
added daily thereafter. Cells were trypsinized and directly
counted by using a Vi-Cell XR cell viability counter
(Beckman Coulter, Brea, CA) at the indicated time points.
Alternatively, MTT assay was performed as previously
described [41].

www.impactjournals.com/oncotarget

Institutional Review Board Approval (13-0692P6H) was obtained prior to initiation of the project.
Surgically resected NSCLC cases from 2006-2010 from
our institution were screened for inclusion in this study.
Cases were excluded if the primary tumor was not of lung
origin or if inadequate pathological material existed. A
total of 216 lung cancer cases were used to build the tissue
microarrays (TMAs). A variety of histologic types were
selected, including 83 adenocarcinomas and 102 squamous
cell carcinomas (for complete list see Supplementary
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Table 2). Pathologic features (tumor grade, histologic type,
presence of lymphovascular invasion etc.) were abstracted
from pathology records and patient charts. Treatment
and outcome data were collected by the Markey Cancer
Center (MCC) Cancer Research Informatics Shared
Resource Facility and the Kentucky Cancer Registry.
Our pathologist then selected appropriate blocks and
identified tumor areas on H&E stained slides for inclusion
in the TMA. For each case, three 2-mm tissue cores were
removed from each formalin-fixed, paraffin embedded
(FFPE) archival tumor block, and were transferred to
recipient paraffin blocks using a TMArrayer TM (Pathology
Devices, Westminster, MD). Listing of randomly-sorted
samples for allocation into the recipient TMA was
generated by the MCC Biostatistics and Bioinformatics
Shared Resource Facility, and then assembled into TMA
blocks (12 in total) by the MCC Biospecimen and Tissue
Procurement Shared Resource Facility. After construction,
TMA blocks were heated at 45° C for 1 hr and then cooled
to complete assembly. S100A4 expression was assessed
by IHC staining as previously reported [7, 42] and scored
by a pathologist blinded to clinical variables. Out of 216
cases included in the TMA, 4 were excluded from analysis
due to folded or absent tissue cores. In the remaining 212
cases, a semi-quantitative scale was used to score S100A4
expression as follows: negative (0), weakly positive (1),
moderately positive (2), and strongly positive (3) (Figure
2). Results from each of the three tissue cores were
averaged together to produce a final score for each tumor.
S100A4 overexpression was defined as a final score >2.5.

Whitney U test, where appropriate. For categorical
variables, differences between groups were analyzed using
chi-squared or Fisher’s exact test, where appropriate. All
tests were two-tailed. Survival differences were assessed
via log-rank test. Significance was reached when P <
0.05. Statistical analyses were performed using GraphPad
software (La Jolla, CA). For data mining, a lung cancer gene
expression dataset [43] generated by The Cancer Genome
Atlas (TCGA Research Network, http://cancergenome.nih.
gov/) was accessed and visualized using The Oncomine™
Platform (Life Technologies, Ann Arbor, MI).
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NF-κB activity assays
For NF-κB luciferase reporter assays, cells grown
in a 24-well plate were co-transfected with 0.25 μg of the
NF-κB reporter (A gift from Dr. Yanan Tian, Texas A& M
University) along with pRL-TK Renilla control reporter
at a 50:1 ratio for 24 hrs. Then, cells were induced by 5
ng/ml TNF-α, vehicle control with or without niclosamide
at the indicated concentration for 24 hrs. Then, cells were
collected and luciferase activity was measured using
the Dual-Luciferase Reporter Assay System (Promega,
Madison, WI). These data are presented as a relative value
to internal control or fold induction as individual control.
To detect NF-κB p65 nuclear translocation, cells
were serum-starved overnight and then stimulated with
5 ng/ml of TNF-α for 4 hrs. For niclosamide treatment,
cells were pretreated with DMSO (control) or 0.5 μM
or 1 μM niclosamide for 48 hrs before serum starvation,
then stimulated with 5 ng/ml of TNF-α for 4 hrs. Cell
fractionation was then performed as described previously
[41].
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